92123-05-2

Upstream product

• 6979-94-8 2',3',5'-tri-O-acetyl-guanosine 
• 118-00-3 G 
• 16321-99-6 2-amino-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine 
• 882-33-7 diphenyldisulfane 

Downstream Products

• 1379453-77-6 N₆-phenethyl-2-phenylthioadenosine 
• 92123-07-4 Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(2-benzenesulfonyl-6-methoxy-purin-9-yl)-tetrahydro-furan-3-yl ester 
• 120524-35-8 N⁶-cyclopentyl-2-(phenylsulfonyl)adenosine 2',3',5'-triacetate 
• 120524-38-1 2-(phenylsulfonyl)-N⁶-(1-naphthylmethyl)adenosine 
• 120524-32-5 (2R,3R,4S,5R)-2-[6-(2,2-Diphenyl-ethylamino)-2-phenylsulfanyl-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 120524-33-6 (2R,3S,4R,5R)-2-Hydroxymethyl-5-{6-[(naphthalen-1-ylmethyl)-amino]-2-phenylsulfanyl-purin-9-yl}-tetrahydro-furan-3,4-diol 
• 120524-37-0 N⁶-cyclohexyl-2-(phenylsulfonyl)adenosine 
• 120524-36-9 N⁶-cyclopentyl-2-(phenylsulfonyl)adenosine 
• 120524-31-4 (2R,3R,4S,5R)-2-(6-Cyclohexylamino-2-phenylsulfanyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 120524-30-3 (2R,3R,4S,5R)-2-(6-Cyclopentylamino-2-phenylsulfanyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 120524-34-7 6-chloro-2-(phenylsulfonyl)-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
• 92123-06-3 Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(6-methoxy-2-phenylsulfanyl-purin-9-yl)-tetrahydro-furan-3-yl ester 

Relevant academic research and scientific papers

Essential Structural Profile of Novel Adenosine Derivatives as Antiplatelet Aggregation Inhibitors Based on 3D-QSAR Analysis Using CoMFA, CoMSIA, and SOMFA

Abstact: —In this study, comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), and the self-organizing molecular field analysis (SOMFA) were performed on a series of novel adenosine derivatives. Significant correlation coefficients (CoMFA, q2 = 0.560, r2 = 0.940, F value = 71.850, and SEE = 0.097; CoMSIA, q2 = 0.528, r2 = 0.943, F value = 29.29 and SEE = 0.108; SOMFA, r2 = 0.615, r2cr= 0.577, F value = 60.797, and SEE = 0.226) were obtained, and the generated models were validated using test sets. By analyzing the corresponding contour maps in detail, new adenosine derivatives with potential efficacy were designed for synthesis in the future.

Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents

A series of novel N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines were synthesized, and their human antiplatelet aggregation activities were evaluated by the stimulation of adenosine 5′-diphosphate (ADP). Some of these compounds showed strong activity, among which compound 5b11 displayed the highest activity with an IC50 value of 29 ± 3 μM. Furthermore, five compounds were tested against arachidonic acid (AA)-induced human platelet aggregation. The results showed that compound 5b10 exhibited the highest activity with an IC50 value of 3 ± 2 μM. The adenosine derivatives substituted with a phenethyl group at the N6 position and a methylthio or ethylthio group at the C-2 position displayed high antiplatelet aggregation activity.

CONVERSION OF GUANOSINE INTO 2-AMINOMETHYLINOSINE (2-HOMOGUANOSINE)

2-Aminomethylinosine (1), a one-carbon extended homolog of an exocyclic amino group of guanosine, was synthesized from guanosine by the use of a newly developed protection and deprotection method.Introduction of a methoxy group into the 6-position of 2-benzenesulfonyl-purine riboside facilitated a nucleophilic substitution with cyanide to afford 2-cyano-6-methoxypurine riboside (11) which was subsequently hydrogenated and demethylated with trimethylsilyl iodide to afford 1.KEYWORDS - 2-substituted purine nucleoside ; 2-homoguanosine; guanosine; cyanation; benzenesulfonyl group; trimethylsilyl iodide; demethylation; non-aqueous diazotization